PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
32.68%
Some net income increase while TRVN is negative at -14.97%. John Neff would see a short-term edge over the struggling competitor.
80.19%
D&A growth well above TRVN's 9.27%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
-398.37%
Both lines show negative yoy. Martin Whitman would see an industry or cyclical factor reducing tax deferrals for both players.
30.65%
SBC growth well above TRVN's 11.55%. Michael Burry would flag major dilution risk vs. competitor’s approach.
27.89%
Slight usage while TRVN is negative at -337.16%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-35.29%
Negative yoy AP while TRVN is 0.00%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
66.06%
Some yoy usage while TRVN is negative at -226.14%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
30.65%
Lower 'other non-cash' growth vs. TRVN's 121.01%, indicating steadier reported figures. David Dodd would confirm no missed necessary write-downs or gains.
-19.98%
Both yoy CFO lines are negative, with TRVN at -74.22%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-32.37%
Both yoy lines negative, with TRVN at -1.47%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-271.58%
Both yoy lines negative, with TRVN at -209.65%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
69.11%
We repay more while TRVN is negative at -52.21%. John Neff notes advantage in lowering leverage if competitor is ramping up debt or repaying less.
-69.14%
Negative yoy issuance while TRVN is 5992.81%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.